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Aim: To determine postpartum glucose tolerance status among women with gestational
diabetes mellitus (GDM) recruited under the Women In India with GDM Strategy (WINGS)
Model of Care (MOC).
Methods: Through the WINGS MOC programme, 212 women with GDM were followed till
delivery between November 2013 and August 2015. All women were advised to return for
a postpartum oral glucose tolerance test (OGTT) 6–12 weeks after delivery. A multivariate
logistic regression (MLR) model was developed to identify the risk factors for postpartum
dysglycemia which was defined as presence of diabetes (DM) or prediabetes.
Results: 203/212(95.8%) women completed their postpartum OGTT. Of the 161 women
(79.3%) who came back for the test between 6 and 12 weeks, 2(1.2%) developed DM, 5
(3.1%), isolated IFG, 13(8.1%), isolated IGT and 5(3.1%) combined IFG/IGT [dysglycemia 25
(15.5%)]. 136 women (84.5%) reverted to normal glucose tolerance (NGT). Of the 42 women
who came back between 12 weeks and a year, 5(11.9%) developed DM, 10(23.8%), isolated
IFG and 1(2.4%) combined IFG/IGT [dysglycemia 16(38.1%)]. 26/42 women (61.9%) reverted
to NGT. Thus overall dysglycemia occurred in 41/203 women (20.2%). MLR showed that
BMI P25 kg/m2 was significantly associated with postpartum dysglycemia (odds ratio:
4.47; 95% confidence interval: 1.8–11.2, p = 0.001).ing Center
ai 600 086,
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one year postpartum, and BMI P25 kg/m2 increased this risk four-fold. Early postpartum
screening can identify high risk women and help plan strategies for prevention of type 2
diabetes in the future.
 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
With the prevalence of type 2 diabetes (T2DM) and predia-
betes growing in epidemic proportions, it is extremely
important to implement strategies to delay or prevent the
onset of T2DM among high risk populations. The incidence
of gestational diabetes mellitus (GDM), the most common
metabolic disorder during pregnancy, is also increasing
worldwide owing to advancing maternal age and increasing
obesity rates [1,2]. Women with previous history of GDM
are at seven fold higher risk of developing T2DM in the
future compared to their counterparts without GDM [3,4].
GDM also confers an increased risk of short term and long
term health consequences such as preeclampsia, fetal
macrosomia, shoulder dystocia and cesarean delivery [5,6].
This calls for improved screening and treatment for GDM
with the aim of improving maternal and fetal outcomes
[7,8].
The American Diabetes Association (ADA) recommends
that women with GDM be reassessed for glycemic status at
6 weeks postpartum [9]. The Fourth International Workshop
on GDM also recommended that glucose tolerance should
be reevaluated 6–12 weeks postpartum [10]. Despite the
elevated risk for diabetes and the recommendations for close
follow-up, opportunities for postpartum screening are fre-
quently missed [11–17]. Postpartum screening rates usually
vary from 14% in usual care, to 60% in randomized control tri-
als [18]. The Translating Research Into Action for Diabetes
(TRIAD) study has shown that although rates of postpartum
screening have increased since the 1990s, it was still only
53.8% in 2006 [11].
Studies have shown that conversion to T2DM following
GDM occurs earlier in South Asians compared to other ethnic
groups [19–21]. In the current study, we sought to determine
the frequency of dysglycemia in the early postpartum period,
and to identify risk factors predicting postpartum dysg-
lycemia in Asian Indian women with GDM followed prospec-
tively throughout their pregnancy.
2. Methodology
The Women In India with GDM Strategy (WINGS) is a project
undertaken by the International Diabetes Federation (IDF) and
the Madras Diabetes Research Foundation (MDRF), Chennai,
India with the support of Abbott Fund, to tackle the rising
problem of GDM in low-middle income countries (LMIC) such
as India [22]. The project was piloted in Chennai, India, with
the aim of developing a model approach to care in LMICs to
confront the widespread challenges in GDM screening andmanagement. A WINGS GDM Model of Care (MOC) was
developed and carried out in collaboration with several health
centers in Tamil Nadu, India.
According to the WINGS GDM MOC protocol, pregnant
women <28 weeks of gestation were approached for screen-
ing for GDM and recruited under the model. For the purpose
of this paper, ‘‘booking visit” refers to the first antenatal visit
of the pregnant woman to the collaborating health center at
which point they were screened. All baseline data collection
was done at this booking visit, including anthropometry and
body weight.
Sample size was calculated using EpiTools software as was
as follows: with 95% confidence interval (CI), desired precision
estimate of ±0.02(2%), based on previous prevalence rate of
17.8% [23] and drop-out rate of 20%, the sample size was
estimated to be 1080.
Under the IDF WINGS MOC, after screening 1124 pregnant
women, 247 women were diagnosed with GDM using the
International Association of Diabetes and Pregnancy Study
Groups (IADPSG) criteria and 3 were identified as having overt
diabetes. Of the 247 women with GDM, 212 were followed up
throughout their pregnancy and their pregnancy outcomes
were measured. The remaining 35 women moved to their
maternal hometown for continuing their antenatal care and
delivered there and hence could not be followed up. The 212
women who were followed under the MOC were constantly
reminded about the importance of postpartum follow-up
testing and were advised to return for the same 6–12 weeks
after delivery. All women who came for the follow-up testing
were assessed by doing an oral glucose tolerance test (OGTT)
using a 82.5 g oral glucose load (equivalent to 75 g of anhy-
drous glucose) after an overnight fast of at least 8 h. Venous
samples were drawn at fasting and 1 h and 2 h after the glu-
cose load.
Blood samples were collected in sodium fluoride/Na2
EDTA vacutainer tubes to prevent glycolysis. Samples were
transported to a central laboratory within one hour of
collection in cool boxes which had gel packs to maintain
the temperature between 2 and 8 C. Plasma glucose was
measured using an autoanalyser AU2700, (Beckman, Fullerton,
CA). The intra- and inter assay coefficients of variation for the
biochemical assays ranged between 3.1% and 7.6%. The central
laboratory is certified by the College of American Pathologists
(CAP), USA and the National Accreditation Board for Testing
and Calibration Laboratories (NABL), Government of India.
The study was approved by the Independent Ethics Committee
of the Madras Diabetes Research Foundation (MDRF), and
written informed consent was obtained from all participating
women.
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Analyses of data was done using Windows based SPSS statis-
tical package (version 15.0, Chicago, IL). Descriptive analyses
were performed for specific variables between women con-
verting to diabetes and non converters and unadjusted com-
parisons between these groups were made using t-tests or
Chi square tests. A multivariate logistic regression model
was developed using dysglycemia [diabetes and or predia-
betes (IGT or IFG or both)] as the dependent variable and pre-
dictor variables which were significant in the bivariate
analysis as the independent variable.
2.2. Definitions
The following definitions were used to classify diabetes (DM)
or prediabetes [impaired fasting glucose (IFG) and/or impaired
glucose tolerance (IGT)] or normal glucose tolerance (NGT)
after the postpartum follow-up OGTT [24].Glycemic status Fasting plasma
glucose level2-H plasma
glucoseDiabetes (DM) P126 mg/dl
(7.0 mmol/l)P200 mg/dl
(11.1 mmol/l)Isolated IFG 100–125 mg/dl
(5.5–6.9 mmol/l)<140 mg/dl
(<7.8 mmol/l)Isolated IGT <100 mg/dl
(<5.5 mmol/l)140–199 mg/dl
(7.8–11 mmol/l)Combined IFG/IGT 100–125 mg/dl
(5.5–6.9 mmol/l)140–199 mg/dl
(7.8–11 mmol/l)NGT <100 mg/dl
(<5.5 mmol/l)<140 mg/dl
(<7.8 mmol/l)For the purpose of this paper, women who developed dysg-
lycemia (diabetes or prediabetes) are referred to as ‘‘convert-
ers” and those who reverted to NGT are referred to as ‘‘non
converters”.3. Results
203/212(95.8%) women completed their postpartum OGTT. Of
these 203 women, 161(79.3%) came back for postpartum
follow-up testing between 6 and 12 weeks, while the remain-
ing 42(20.7%) women came back between 12 weeks and a year
after the delivery. Of the 161 women (79.3%) who came back
for the test between 6 and 12 weeks, 2(1.2%) developed DM,
5(3.1%), isolated IFG, 13(8.1%), isolated IGT and 5(3.1%) com-
bined IFG/IGTwhile 136(84.5%) reverted to normal glucose tol-
erance (NGT). Of the 42 women who came back within a year,
5(11.9%) developed DM, 10(23.8%), isolated IFG and 1(2.4%)
combined IFG/IGT, while 26(61.9%) reverted to NGT. Hence
dysglycemia was detected in 25(15.5%) women between 6
and 12 weeks and in 16 women (38.1%) between 12 weeks
and 1 year. Thus dysglycemia occurred in a total of 41/203
women (20.2%) within 1 year of delivery (Table 1).
Age, BMI, gestational week at booking, HbA1c, family his-
tory of diabetes and PCOD were higher among women with
GDM who converted to dysglycemia when compared to those
who reverted back to NGT. However, only BMI, HbA1c (atbooking) and previous history of GDM reached statistical sig-
nificance (Table 2).
Multivariate logistic regression showed that a baseline BMI
of P25 kg/m2 [odds ratio (OR) 4.4, CI: 1.78–11.20, p
value = 0.001] was significantly associated with postpartum
dysglycemia after adjusting for HbA1c and previous history
of GDM (Table 3).4. Discussion
Several studies have shown that GDM is an important risk
factor for development of T2DM. Depending on various fac-
tors like ethnicity, protocols used, follow-up duration and
the diagnostic criteria used, conversion rates vary from 2.6%
to as high as 70% [25]. Studies from the west have shown that
during a 5 year follow-up after GDM, the cumulative inci-
dence rate of diabetes was 50% [26]. In a previous retrospec-
tive study, we showed that 56.3% of women with a history
of GDM developed diabetes within 5 years after delivery [27].
Kale et al. [28] from northern India reported conversion rates
of 52% after a mean follow-up period of 4.5 years. The present
study is of interest because we show that conversion to dysg-
lycemia occurs rapidly. In this cohort, 15.5% of women were
detected to have dysglycemia by 12 weeks while an additional
38.1% were detected to have dysglycemia between 12 weeks
and 1 year of delivery, highlighting the importance of early
screening for diabetes. It also shows the value of screening
within 1 year window period in women who missed screen-
ing or screened negative at 12 weeks postpartum.
Given that T2DM is an important sequel of GDM, close
postpartum follow-up is essential. It is also important to iden-
tify women at greatest risk of postpartum T2DM, to help plan
prevention and intervention strategies that could improve
health outcomes.
Previous investigations have demonstrated that conver-
sion to dysglycemia is attributed to several risk factors includ-
ing maternal age, BMI, family history of T2DM, previous
history of GDM, HbA1c, weight gain during pregnancy and
birth weight of the baby [29,30]. Several studies have revealed
that maternal BMI at baseline (independent of weight gain) is
an independent risk factor for subsequent conversion to dys-
glycemia [26,31–33]. A study from Denmark reported that BMI
of P25 kg/m2 was one of the main predictors of postpartum
glucose abnormalities [4]. HbA1c is also reported as a predic-
tor for diabetes following GDM [34,35]. As seen in previous
studies, the current study also revealed that BMI P25 kg/m2
is an independent risk factors for postpartum dysglycemia
in south Indian women. While other traditional risk factors
demonstrated a trend towards increased risk for GDM, they
did not reach statistical significance probably due to smaller
sample size.
Several organizations have put forth guidelines for post-
partum follow-up. The American Diabetes Association (ADA)
recommends that women with GDM should undergo screen-
ing for T2DM with OGTT, 6 weeks after delivery [9]. The
National Institute for Health and Care Excellence (NICE) rec-
ommends fasting plasma glucose (FPG) testing at 6 weeks
postpartum [36], while WHO recommends an OGTT at
6 weeks or after [37].
Table 1 – Postpartum follow up status and glucose tolerance status.
S. no. Total GDM women followed up n = 203
Period of follow up 6–12 weeks (n = 161) 12 weeks to 1 year (n = 42)
Glucose tolerance status
1 Normal glucose tolerance 136(84.5%) 26(61.9%)
2 Isolated IFG 5(3.1%) 10(23.8%)
3 Isolated IGT 13(8.1%) –
4 Combined IFG/IGT 5(3.1%) 1(2.4%)
5 Diabetes 2(1.2%) 5(11.9%)
Dysglycemia (isolated IFG + isolated IGT
+ combined IFG/IGT + Diabetes)
25(15.5%) 16(38.1%)
Total dysglycemia 25 + 16 = 41/203(20.2%)
Table 2 – Comparison of baseline clinical profile of GDM women of converters and non converters to dysglycemia.
S. no. Parameters Converters to
dysglycemia (n = 41)
Non converters to
dysglycemia (n = 162)
p value
1 Age (in years) 29.6 ± 4.2 28.6 ± 4.3 0.37
2 BMI at booking (kg/m2) 28.0 ± 5.0 25.8 ± 4.7 0.01
3 Gestation week at booking (in weeks) 19.2 ± 6.7 17.6 ± 7.2 0.56
4 Weight gain (in kg) 6.4 ± 4.2 7.0 ± 4.1 0.32
5 Gestation week at delivery (in weeks) 37.8 ± 1.6 37.9 ± 2.8 0.21
6 HbA1c at booking (%) 5.5 ± 0.9 5.1 ± 0.8 0.01
HbA1c at booking (IFCC units mmol/mol) (37 ± 6) (32 ± 4)
7 Hemoglobin (%) 11.0 ± 1.3 11.4 ± 1.0 0.30
8 Family history of diabetes 21(51.2%) 71(43%) 0.35
9 Previous history of GDM 3(7.3%) 13(7.9%) 0.008
10 Polycystic ovarian disease 4(9.8%) 9(5.5%) 0.39
11 Birth weight of the baby 3.1 ± 0.60 2.9 ± 0.50 0.05
p < 0.05 is considered significant.
Table 3 – Multivariate logistic regression showing factors associated with conversion to dysglycemia.
Risk factors B SE Odds ratio 95% CI p value
1 BMI P25 kg/m2 1.49 0.468 4.47* 1.785–11.206 0.001
2 HbA1c at booking (%) 0.321 0.201 0.725 0.488–1.076 0.11
3 Previous history of GDM 0.334 0.709 0.715 0.178–2.877 0.637
p < 0.05 is considered significant.
* Odds ratio adjusted for HbA1c at booking and previous history of GDM.
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several highly respected organizations, postpartum screening
rates have ranged from 23% to 58% between 5 weeks and
1 year following delivery [38–43]. Several potential explana-
tions have been offered for such poor rates of postpartum
follow-up screening. One is the uncertainty between primary
and secondary care responsibilities for screening. In some
settings, GDM follow-up is not considered a clinical priority
[44]. This could be due to lack of awareness among health
care professionals about various guidelines. Patient related
barriers include emotional stress and difficulty with adjusting
to motherhood and difficulty to come for postpartum testing
in fasting state when exclusively breastfeeding through the
night [45].In the present study also, several barriers to postpartum
screening were observed. Logistic issues such as distance
from the hospital, demands of household tasks and lack of
shared responsibility for the newborn impede postpartum
screening. However, we were able to ensure a 95.8% follow-
up rate which surpasses typically expected rates of follow-
up seen in high, middle and low income settings. Review of
latest evidence regarding rates of postpartum follow-up by
Tovar et al. [46] shows that postpartum follow-up rates varied
greatly but were generally reported to be poor: between 34%
and 73%. One reason for the high success rate in this study
could be because we constantly reminded our women during
their pregnancy to return for postpartum follow-up between 6
and 12 weeks after delivery. Efforts were taken to increase the
26 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 1 7 ( 2 0 1 6 ) 2 2 –2 7postpartum screening rates by sending reminders to the
patients, by contacting them through phone calls and arrang-
ing home visits for testing. In our experience one important
aspect which affects the postpartum follow-up is that many
womenmove to their maternal homes for delivery, a social cus-
tom practiced in many parts of India. This was a major limita-
tion of the study, as postpartum follow up testing which was
planned to be completed within 12 weeks was delayed up to
a year for women who went to their maternal homes for deliv-
ery did not return back for postpartum testing until the end of
one year. In view of the rapid conversion to T2DM occurring in
this population after GDM, it is important to emphasize in
future programmes, the value of early post-partum screening
even within 12 weeks, with cultural adaptations to achieve
the same, including testing at the city where the mother
resides. This would increase the scope for introducing preven-
tive measures to reduce the risk of progression to dysglycemia.
Another limitation is that we did not include diet and physical
activity assessment or advise as part of WINGS post-partum
follow up. Finally we did not collect data on exclusive breast
feeding which is yet another limitation of our study.
In summary, the WINGS project has demonstrated that
through sustained efforts, a near total post-partum follow-
up is achievable. The importance of this in Asian Indian
women, is demonstrated by the high rates and rapid conver-
sion to dysglycemia seen amongst our population. Early
screening in the postpartum period particularly in overweight
women can identify women who are likely to progress to dys-
glycemia and thus help plan preventive strategies for delaying
the onset of T2DM in them.
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